Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00627
|
|||||
| Drug Name |
Acebutolol
|
|||||
| Synonyms |
(+-)-3'-Acetyl-4'-(2-hydroxy-3-(isopropylamino)propoxy)butyranilide; (+-)-Acebutolol; (+-)-N-(3-Acetyl-4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)butanamide; 1-(2-Acetyl-4-n-butyramidophenoxy)-2-hydroxy-3-isopropylaminopropane; 3'-(Acetyl-4'-(2-hydroxy-3-(isopropylamino)propoxy)butyranilide; 3'-Acetyl-4'-(2-hydroxy-3-(isopropylamino)propoxy)butyranilide; 3'-Acetyl-4'-(2-hydroxy-3-isopropylaminopropoxy)butyranilid; 5'-Butyramido-2'-(2-hydroxy-3-isopropylaminopropoxy)acetophenone; Acebrutololum; Acebrutololum [INN-Latin]; Acebutolol (USAN/INN); Acebutolol HCL; Acebutolol [USAN:INN:BAN]; Acebutololo; Acebutololum; Acebutololum [INN-Latin]; Acetobutolol; Acetobutolol [INN-Spanish]; Dl-Acebutolol; M & B 17803A; M&B-17803 A; N-(3-Acetyl-4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl)butanamide; N-[3-acetyl-4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]butanamide; N-[3-acetyl-4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]butanamide; N-{3-acetyl-4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}butanamide; Neptal; Prent; Prent (TN); RP 21823; Sectral; Sectral (TN)
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | High blood pressure [ICD11: BA00] | Approved | [1] | |||
| Ventricular premature beats [ICD11: BC70] | Approved | [1] | ||||
| Therapeutic Class |
Antihypertensive Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C18H28N2O4
|
|||||
| Canonical SMILES |
CCCC(=O)NC1=CC(=C(C=C1)OCC(CNC(C)C)O)C(=O)C
|
|||||
| InChI |
InChI=1S/C18H28N2O4/c1-5-6-18(23)20-14-7-8-17(16(9-14)13(4)21)24-11-15(22)10-19-12(2)3/h7-9,12,15,19,22H,5-6,10-11H2,1-4H3,(H,20,23)
|
|||||
| InChIKey |
GOEMGAFJFRBGGG-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 37517-30-9
|
|||||
| Pharmaceutical Properties | Molecular Weight | 336.4 | Topological Polar Surface Area | 87.7 | ||
| Heavy Atom Count | 24 | Rotatable Bond Count | 10 | |||
| Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 5 | |||
| XLogP |
1.7
|
|||||
| PubChem CID | ||||||
| PubChem SID |
103189011
, 104299258
, 10520758
, 11335787
, 11361026
, 11363385
, 11365947
, 11368509
, 11371586
, 11374422
, 11376671
, 11461998
, 11466097
, 11467217
, 11485235
, 11485914
, 11489156
, 11490389
, 11492617
, 11494305
, 124883487
, 126443068
, 126679412
, 127982055
, 134337777
, 134999047
, 15075320
, 29221166
, 46509113
, 47216767
, 47216768
, 47291119
, 47365171
, 47365172
, 47440234
, 47810742
, 49698901
, 49895324
, 50427938
, 5199954
, 56413043
, 57321077
, 7849397
, 7978630
, 8148212
, 8151358
, 85209697
, 85787903
, 9022
, 99222788
|
|||||
| ChEBI ID |
ChEBI:2379
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | OATP1A2 | Transporter Info | Organic anion transporting polypeptide 1A2 | Substrate | [2] | |
| OCT-1 | Transporter Info | Organic cation transporter 1 | Substrate | [3] | ||
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [4] | ||
| References | ||||||
| 1 | Acebutolol was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Fruit juice inhibition of uptake transport: a new type of food-drug interaction. Br J Clin Pharmacol. 2010 Nov;70(5):645-55. | |||||
| 3 | Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33. | |||||
| 4 | Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.